[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2015120216A - Ингибиторы тирозинкиназы брутона - Google Patents

Ингибиторы тирозинкиназы брутона Download PDF

Info

Publication number
RU2015120216A
RU2015120216A RU2015120216A RU2015120216A RU2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A
Authority
RU
Russia
Prior art keywords
fluoro
oxo
tert
butyl
phthalazin
Prior art date
Application number
RU2015120216A
Other languages
English (en)
Inventor
Ромир ДОМИНИК
Франсиско Хавьер Лопез-Тапиа
Эрик МЕРТЦ
Сун-Сау СО
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2015120216A publication Critical patent/RU2015120216A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (29)

1. Соединение Формулы I,
Figure 00000001
где:
А представляет собой фталазин, возможно замещенный одним или более А';
А' представляет собой трет-бутил, F или оксо;
каждый R1 независимо представляет собой F или гидроксиметил;
m равно 1;
R2 представляет собой метил пиразолил;
n представляет собой 0; и
X представляет собой СН2;
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, выбранное из группы, состоящей из:
6-трет-бутил-8-фтор-2-[4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-фтор-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-гидроксиметил-3-(2-оксо-1,2-дигидро-пиридин-4-ил)-фенил]-2Н-фталазин-1-он;
6-трет-бутил-2-[2,6-дифтор-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-8-фтор-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2H-фталазин-1-он;
6-трет-бутил-8-фтор-2-{2-фтор-4-[6-(1-метил-1Н-пиразол-4-ил)-2-оксо-1,2-дигидро-пиридин-4-ил]-бензил}-2H-фталазин-1-он;
6-трет-бутил-8-фтор-2-[3-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2H-фталазин-1-он; и
6-трет-бутил-8-фтор-2-[2-фтор-5-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он.
3. Способ лечения воспалительного и/или аутоиммунного состояния содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1 или 2.
4. Способ лечения воспалительного состояния, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1 или 2.
5. Способ лечения ревматоидного артрита, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединение по любому из пп. 1 или 2.
6. Способ лечения астмы, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединение по любому из пп. 1 или 2.
7. Фармацевтическая композиция, содержащая соединение по любому из пп. 1 или 2, смешанное по меньшей мере с одним фармацевтически приемлемым носителем, эксципиентом или разбавителем.
8. Применение соединения по любому из пп. 1 или 2 в качестве терапевтически активного вещества.
9. Применение соединения по любому из пп. 1 или 2 для получения лекарственного средства для лечения воспалительного и/или аутоиммунного состояния.
10. Применение соединения по любому из пп. 1 или 2 для лечения воспалительного и/или аутоиммунного состояния.
11. Соединение по любому из пп. 1 или 2 для применения для лечения воспалительного и/или аутоиммунного состояния.
RU2015120216A 2012-11-16 2013-11-13 Ингибиторы тирозинкиназы брутона RU2015120216A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727130P 2012-11-16 2012-11-16
US61/727,130 2012-11-16
PCT/EP2013/073667 WO2014076104A1 (en) 2012-11-16 2013-11-13 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
RU2015120216A true RU2015120216A (ru) 2017-01-10

Family

ID=49584724

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015120216A RU2015120216A (ru) 2012-11-16 2013-11-13 Ингибиторы тирозинкиназы брутона

Country Status (13)

Country Link
US (1) US9458105B2 (ru)
EP (1) EP2920162B1 (ru)
JP (1) JP6088063B2 (ru)
KR (1) KR101713465B1 (ru)
CN (1) CN104812746B (ru)
AR (1) AR093478A1 (ru)
BR (1) BR112015010693A2 (ru)
CA (1) CA2890671A1 (ru)
HK (1) HK1212689A1 (ru)
MX (1) MX2015006162A (ru)
RU (1) RU2015120216A (ru)
TW (1) TW201425297A (ru)
WO (1) WO2014076104A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CN109336864A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型n及其制备方法
CN109485636A (zh) * 2018-10-04 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途
CN109369619A (zh) * 2018-10-04 2019-02-22 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型b及其制备方法
CN109180643A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型a及其制备方法
CN109180642A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类btk抑制剂及其应用
CN109293635A (zh) * 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的p晶型及其制备方法
CN109288830A (zh) * 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类化合物联合用药物组合物
CN109336863A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种新型酞嗪酮类btk抑制剂、制备及其应用
CN109172592A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种抗肿瘤药物组合物
CN109180644A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途
CN109481444A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和酞嗪类btk抑制剂联合用药物组合物及其应用
CN109481443A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394765A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481441A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481442A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109288841A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109223759A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331005A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用
CN109276571A (zh) * 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
US20220411429A1 (en) * 2019-10-30 2022-12-29 Biogen Ma Inc. Condensed pyridazine or pyrimidine as btk inhibitors
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045750A (ja) * 1995-09-20 1998-02-17 Takeda Chem Ind Ltd アゾール化合物、その製造方法及び用途
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
NZ586916A (en) * 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
CN103408533B (zh) * 2008-06-24 2015-08-26 霍夫曼-拉罗奇有限公司 新型取代的吡啶-2-酮和哒嗪-3-酮
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CA2809836C (en) * 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
MX345170B (es) * 2011-05-17 2017-01-19 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
EP2744804B1 (en) * 2011-08-17 2017-05-17 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US8669251B2 (en) * 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
CA2854603A1 (en) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US9499548B2 (en) * 2012-09-13 2016-11-22 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
CA2903137C (en) * 2013-03-05 2017-07-18 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EP2964627B1 (en) * 2013-03-05 2017-03-01 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US9326985B2 (en) * 2013-07-03 2016-05-03 Genentech, Inc. Heteroaryl pyridone and aza-pyridone amide compounds

Also Published As

Publication number Publication date
CA2890671A1 (en) 2014-05-22
EP2920162B1 (en) 2017-04-19
KR20150084061A (ko) 2015-07-21
WO2014076104A1 (en) 2014-05-22
CN104812746B (zh) 2017-03-08
HK1212689A1 (zh) 2016-06-17
US9458105B2 (en) 2016-10-04
BR112015010693A2 (pt) 2017-07-11
AR093478A1 (es) 2015-06-10
KR101713465B1 (ko) 2017-03-07
JP2015537016A (ja) 2015-12-24
TW201425297A (zh) 2014-07-01
JP6088063B2 (ja) 2017-03-01
CN104812746A (zh) 2015-07-29
MX2015006162A (es) 2015-08-14
EP2920162A1 (en) 2015-09-23
US20150291525A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
RU2013121788A (ru) Ингибиторы репликации вич
JP2015504067A5 (ru)
RU2019131017A (ru) Соединения гетероарила в качестве ингибиторов btk и их применение
RU2014102773A (ru) Новые кристаллические формы ингибиторов дипептидилпептидазы-iv
JP2013531031A5 (ru)
JP2014500295A5 (ru)
RU2016129953A (ru) Фармацевтические комбинации
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2013513613A5 (ru)
RU2012114846A (ru) Соединение глицина
RU2015133450A (ru) Соединения имидазопиридина и их применение
RU2013154412A (ru) Аминопиримидины в качестве ингибиторов syc
JP2015517566A5 (ru)
JP2011006480A5 (ru)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
JP2014505107A5 (ru)
RU2015123499A (ru) Соединения замещенной триазолбороновой кислоты
JP2014513722A5 (ru)
JP2013523814A5 (ru)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2015121037A (ru) Производные фенилэтилпиридина в качестве ингибиторов pde-4
RU2015141360A (ru) Ингибиторы тирозинкиназы брутона

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180129